Arizona Health Sciences

Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.

TitleInhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.
Publication TypeJournal Article
Year of Publication2011
AuthorsSukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F, King T
JournalMol Pain
Volume7
Pagination81
Date Published2011
ISSN1744-8069
KeywordsAnimals, Bone Remodeling, Breast Neoplasms, Cell Line, Tumor, Female, Femur, Imidazoles, Mice, p38 Mitogen-Activated Protein Kinases, Pain Management, Pyridines, Signal Transduction
Abstract

BACKGROUND: Mechanisms driving cancer-induced bone pain are poorly understood. A central factor implicated to be a key player in the process of tumorigenesis, osteoclastogenesis and nociception is p38 MAPK. We determined the role of p38 MAPK in a mouse model of breast cancer induced bone pain in which mixed osteolytic and osteoblastic remodeling occurs.

RESULTS: In cancer-treated mice, acute as well as chronic inhibition of p38 MAPK with SB203580 blocked flinching and guarding behaviors in a dose-dependent manner whereas no effect on thresholds to tactile stimuli was observed. Radiographic analyses of bones demonstrated that chronic inhibition of p38 MAPK reduced bone loss and incidence of spontaneous fracture in cancer-treated mice. Histological analysis of bones collected from mice treated with the p38 MAPK inhibitor showed complete absence of osteoblastic growth in the intramedullary space as well as significantly reduced tumor burden.

CONCLUSIONS: Blockade of non-evoked pain behaviors but not hypersensitivity suggests differences in the underlying mechanisms of specific components of the pain syndrome and a possibility to individualize aspects of pain management. While it is not known whether the role of p38 MAPK signaling can be expanded to other cancers, the data suggest a need for understanding molecular mechanisms and cellular events that initiate and maintain cancer-induced bone pain for effective management for both ongoing pain as well as breakthrough pain.

DOI10.1186/1744-8069-7-81
Alternate JournalMol Pain
PubMed ID22014040
PubMed Central IDPMC3212934
Grant ListCA23074 / CA / NCI NIH HHS / United States
DA016431 / DA / NIDA NIH HHS / United States
DA019877 / DA / NIDA NIH HHS / United States
Faculty Member Reference: 
Frank Porreca, PhD
Todd Vanderah, PhD